News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MycoLogics, Inc. To Develop A High Throughput Screen Used To Identify Antifungal Drugs


10/19/2005 5:10:44 PM

MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines against human fungal and parasitic pathogens, today announced award of a Phase I SBIR grant by the Department of Health and Human Services to isolate a new class of compounds by disrupting beta(1,3)-glucan synthesis using a novel assay. The beta(1,3)-glucan polymer is an essential component for fungal growth, it is found in fungi not in humans and is a validated FDA-approved clinical target for antifungals. The patentable assay is scaleable from low throughput to high throughput.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES